It is now clear that what happens outside the cell boundaries in what is designated as the tumor microenvironment can have a significant impact on tumor progression. Host-derived cells are actively recruited into the tumor microenvironment by a large variety of chemokines and growth factors expressed by tumor cells, either from neighboring tissues or from the bone marrow. Vice versa, the bone marrow actively recruits tumor cells and provides a unique environment where through osteoblast and osteoclast activation, tumor cells establish bone metastasis. Over the last four years of funding through this grant we have demonstrated that neuroblastoma cells recruit bone marrow-derived cells as a source of endothelial precursor cells (EPC) and matrix metalloproteinase-9 (MMP-9) expressing CD45 positive inflammatory cells, and that MMP-9 plays a critical role in the establishment of a mature vasculature by promoting endothelial cell coverage with pericytes. We have also obtained evidence that neuroblastoma cells, which lack the ability to express osteoclast activating factors, can stimulate the expression of interleukin-6 (IL-6), an activator of osteoclasts, by bone marrow mesenchymal stem cells (BM-MSC). On the basis of these observations, we hypothesize that bone marrow-derived cells positively contribute to neuroblastoma tumor progression by two specific mechanisms, first by being a source of EPC and inflammatory cells that contribute to the establishment of a mature vasculature in the primary tumor, and second by being a source of IL-6 expressing BM-MSC and of osteoclasts, allowing malignant bone invasion. Our two specific aims are:
Aim #1 : To examine the mechanisms by which neuroblastoma cells recruit bone marrowderived cells, their role in vascular morphogenesis, and the consequences of a lack of pericyte coverage on vascular permeability, drug delivery and clinical outcome.
Aim #2 : To examine the mechanisms by which BM-MSC are stimulated by neuroblastoma cells to activate osteoclasts and trigger bone invasion, and to test therapies interfering with this process. This project aimed at a fundamental understanding of the interactions between neuroblastoma cells and bone marrow-derived cells will identify novel targets for therapeutic intervention based on these interactive pathways.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Program Projects (P01)
Project #
5P01CA081403-10
Application #
7901620
Study Section
Subcommittee G - Education (NCI)
Project Start
Project End
Budget Start
2009-06-01
Budget End
2010-05-31
Support Year
10
Fiscal Year
2009
Total Cost
$232,316
Indirect Cost
Name
Children's Hospital of Los Angeles
Department
Type
DUNS #
052277936
City
Los Angeles
State
CA
Country
United States
Zip Code
90027
Villablanca, Judith G; Ji, Lingyun; Shapira-Lewinson, Adi et al. (2018) Predictors of response, progression-free survival, and overall survival using NANT Response Criteria (v1.0) in relapsed and refractory high-risk neuroblastoma. Pediatr Blood Cancer 65:e26940
Niemas-Teshiba, Risa; Matsuno, Ryosuke; Wang, Larry L et al. (2018) MYC-family protein overexpression and prominent nucleolar formation represent prognostic indicators and potential therapeutic targets for aggressive high-MKI neuroblastomas: a report from the children's oncology group. Oncotarget 9:6416-6432
Webb, Matthew W; Sun, Jianping; Sheard, Michael A et al. (2018) Colony stimulating factor 1 receptor blockade improves the efficacy of chemotherapy against human neuroblastoma in the absence of T lymphocytes. Int J Cancer 143:1483-1493
Pinto, Navin; DuBois, Steven G; Marachelian, Araz et al. (2018) Phase I study of vorinostat in combination with isotretinoin in patients with refractory/recurrent neuroblastoma: A new approaches to Neuroblastoma Therapy (NANT) trial. Pediatr Blood Cancer 65:e27023
DuBois, Steven G; Mosse, Yael P; Fox, Elizabeth et al. (2018) Phase II Trial of Alisertib in Combination with Irinotecan and Temozolomide for Patients with Relapsed or Refractory Neuroblastoma. Clin Cancer Res 24:6142-6149
Cho, Hwang Eui; Min, H Kang (2017) Analysis of fenretinide and its metabolites in human plasma by liquid chromatography-tandem mass spectrometry and its application to clinical pharmacokinetics. J Pharm Biomed Anal 132:117-124
Zheng, Tina; Ménard, Marie; Weiss, William A (2017) Neuroblastoma Metastases: Leveraging the Avian Neural Crest. Cancer Cell 32:395-397
Erdreich-Epstein, Anat; Singh, Alok R; Joshi, Shweta et al. (2017) Association of high microvessel ?v?3 and low PTEN with poor outcome in stage 3 neuroblastoma: rationale for using first in class dual PI3K/BRD4 inhibitor, SF1126. Oncotarget 8:52193-52210
Marachelian, Araz; Villablanca, Judith G; Liu, Cathy W et al. (2017) Expression of Five Neuroblastoma Genes in Bone Marrow or Blood of Patients with Relapsed/Refractory Neuroblastoma Provides a New Biomarker for Disease and Prognosis. Clin Cancer Res 23:5374-5383
Borriello, Lucia; Nakata, Rie; Sheard, Michael A et al. (2017) Cancer-Associated Fibroblasts Share Characteristics and Protumorigenic Activity with Mesenchymal Stromal Cells. Cancer Res 77:5142-5157

Showing the most recent 10 out of 150 publications